IL6R and COVID-19: The PBMC of adult COVID-19 patients treated (n = 12) or not (n = 4) by Tocilizumab, an anti-IL-6R mAb drug, had similar cell counts of total γδ T lymphocytes (on average 59 vs. 45 γδ T cells per sample, respectively), as for both TCRVγ9 and TCRVγnon9 subsets.